Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

8.99
+0.48005.64%
Post-market: 8.990.00000.00%16:10 EDT
Volume:247.01K
Turnover:2.19M
Market Cap:294.86M
PE:-10.85
High:9.06
Open:8.45
Low:8.25
Close:8.51
Loading ...

BRIEF-Neuropace To Continue To Work With CMS On MS-Drg Improvements

Reuters
·
01 Aug

Neuropace Inc - to Continue to Work With CMS on MS-Drg Improvements

THOMSON REUTERS
·
01 Aug

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

GlobeNewswire
·
01 Aug

NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025

GlobeNewswire
·
30 Jul

NeuroPace (NPCE) Receives a Buy from Leerink Partners

TIPRANKS
·
26 Jun

Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE)

TIPRANKS
·
25 Jun

NeuroPace Appoints New CFO Amid Strategic Shift

TIPRANKS
·
25 Jun

NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed

TIPRANKS
·
25 Jun

BRIEF-NeuroPace Says Rebecca Kuhn Departs As CFO, To Serve In Advisory Role

Reuters
·
25 Jun

Press Release: NeuroPace Announces Strategic CFO Transition

Dow Jones
·
25 Jun

Cantor Fitzgerald Remains a Buy on NeuroPace (NPCE)

TIPRANKS
·
16 Jun

NeuroPace Inc. Conducted Annual Stockholders' Meeting Virtually

Reuters
·
13 Jun

UBS Reaffirms Their Buy Rating on NeuroPace (NPCE)

TIPRANKS
·
12 Jun

Analysts Offer Insights on Healthcare Companies: MAIA Biotechnology, Inc. (MAIA) and NeuroPace (NPCE)

TIPRANKS
·
09 Jun

BRIEF-Neuropace Inc - Enters Into Credit Agreement With Midcap Funding Iv Trust

Reuters
·
05 Jun

Press Release: NeuroPace Secures Up to $75 Million in Debt Financing

Dow Jones
·
05 Jun

Cantor Fitzgerald Sticks to Their Buy Rating for NeuroPace (NPCE)

TIPRANKS
·
02 Jun

NeuroPace Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
28 May

Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal

TIPRANKS
·
28 May

NeuroPace initiated with a Buy at H.C. Wainwright

TIPRANKS
·
28 May